Introduction
Systemic sclerosis (SSc) is a connective tissue disease characterised by fibrosis of the skin and internal organs. Disease manifestations are a consequence of a pathologic triad of inflammation, vasculopathy and fibrosis 1 ( Figure 1 ). SSc is clinically divided into subtypes, limited cutaneous systemic sclerosis (lcSSc) and diffuse cutaneous systemic sclerosis (dcSSc), based on the extent of skin thickening present. 2 There is significant research activity focused on discovering new disease-modifying agents, [3] [4] [5] [6] yet at the same time, there is a lack of well-developed and fully validated multi-organ system outcome measures for use in clinical trials required to test novel therapies. 7 The European Scleroderma Trials and Research Group (EUSTAR) Activity Index (EScSG-AI), 8 revised in 2017, 9 is the single activity index developed for SSc. The EScSG-AI has faced criticism for its lack of face and content validity. 9 Other outcome measures used in clinical trials, such as the Medsger Severity Scale (MSS) 10 and modified Rodnan Skin Score (mRSS), 11 have only limited accuracy when measuring response to a therapeutic intervention. The MSS is a measure of disease severity, capturing both disease activity and damage, and quantifies the overall effect of SSc on nine affected organ systems. The mRSS is only applicable to patients with dcSSc and neither score is specific to disease activity.
In this article, we summarise the available SSc outcome measures and their psychometric properties. We outline the proposed methodology for the development of the novel Scleroderma Clinical Trials Consortium (SCTC) Activity Index (SCTC-AI), with particular reference to the process of validation according to the Outcome Measures in Rheumatology (OMERACT) filter of truth, discrimination and feasibility. 12 
Outcome measures in SSc

Composite Response Index for Clinical Trials in Early Diffuse Cutaneous Systemic Sclerosis
The Composite Response Index for Clinical Trials in Early Diffuse Cutaneous Systemic Sclerosis (CRISS) was developed for use in clinical trials of early dcSSc as a measure of the likelihood of improvement following exposure to therapy. 13 Elements of the CRISS are change in mRSS, forced vital capacity (FVC), Health Assessment Questionnaire Disability Index (HAQ DI) and patient and physician global assessments of disease status over the follow-up period. Each of these scores contributes to an overall value between 0 and 1.0, with a score ≥0.6 considered to predict high probability of improvement. A patient cannot be considered improved if there has been significant decline in cardio-pulmonary-renal involvement. The development of CRISS relied upon comparison of items to expert physician assessment of disease status as the gold standard measure of patient improvement. CRISS does not explicitly include all affected organ systems, such as the gastrointestinal and renal systems or vascular disease. It is suggested that the physician and patient global assessments of disease capture these manifestations. 13 Post hoc analysis of randomised controlled trials assessing the performance of CRISS has been limited by missing data or not all elements of the CRISS instrument being administered in the trial. 13, 14 Recently presented abstracts suggest that CRISS can distinguish between treatment and placebo arms in two clinical trials. 14, 15 
Modified Rodnan Skin Score
The mRSS is a commonly used primary outcome measure in trials of dcSSc. 16 Change in mRSS is an accepted reflection of disease activity, can predict mortality and is considered a surrogate marker for internal organ involvement. 2, 17, 18 This is only applicable to patients with diffuse disease, as there is little change in mRSS noted in lcSSc. 16 Attenuation and improvement in peak skin scores is associated with reduced mortality. 11, 19 However, there is a phenomenon of regression to the mean in clinical trials studying cutaneous disease as the natural history of cutaneous involvement is improvement after an early peak in skin score. 20 Baseline skin score is the strongest predictor of either improvement or worsening of mRSS. [20] [21] [22] If there is a heavy reliance on skin scores to measure disease activity, assessment is likely limited to those patients who have early dcSSc.
Medsger Severity Score
The MSS was developed as an organ-specific measure of the total effect of SSc on organ function. 10 The scale was developed by consensus and data-driven methods using the Pittsburgh SSc patient cohort. The MSS intentionally combines both reversible and irreversible components of disease, capturing activity and damage. Severity of disease in each organ system is ranked on a 0-4 scale, with 4 representing end-stage disease.
The MSS is a commonly used outcome measure in clinical trials and is often used as a single-composite score. The MSS measures severity in individual organ systems and is unweighted and was not originally designed to be used as summed, total score of overall disease severity and the authors felt that a summed MSS may misrepresent the overall severity of disease. 10 More recently, using item response theory to estimate the 'weights' of individual MSS organ scores, Harel et al. tested summed MSS and weighted MSS scores and the physician global assessment of disease severity against various patient-reported outcomes (PROs) of overall disease status and organ-specific symptoms. This study found that the summed and weighted MSS scores showed discriminative validity and were predictive for mortality. 23 However, if the MSS is used as a measure of response to therapy, a change in MSS score may not reflect a change in disease activity but accrual of damage, complicating the interpretation of the effect of a therapeutic intervention.
Patient Reported Outcomes
The importance of including patient perspectives and measuring health-related quality of life is established. 24 Patient reported outcomes (PROs) offer complimentary information to objective measures of disease status and are frequently incorporated into clinical trials and practice. 25 Some organ systems lack a consensus definition of disease involvement and present difficulties in objective measurement of disease status, suggesting a potential role for PROs to indicate disease activity.
The Raynaud's condition score (RCS) is the only SScspecific PRO to have been tested and shown to have validity and reliability within a randomised controlled trial. 26 Variable validation of PROs and the lack of SSc-specific measures make comparison between cohorts and clinical trials difficult. 27 In addition, minimal change in PRO scores over time has been reported, suggesting poor sensitivity to change in disease status. 7, 28 PROs lack specificity for an organ of interest or SSc itself, as co-morbidities such as depression can have a significant effect on patient assessment of disease activity and severity. [29] [30] [31] 
SCTC Damage Index
Organ damage is an important consideration in the management of any chronic disease, as it is associated with organ failure and mortality. 32 The Scleroderma Clinical Trials Consortium (SCTC), an international collaboration of researchers and clinicians with expertise in management and research of SSc, recently developed a damage index (SCTC-DI).
The SCTC-DI is a weighted, multi-system instrument that measures disease and treatment-related damage across cutaneous, musculoskeletal, vascular, gastrointestinal, respiratory, cardiovascular and renal organ systems. Analysis of the SCTC-DI in the derivation cohort has shown good discriminatory capacity for mortality and morbidity (area under the curve (AUC) = 0.773 and 0.687, respectively) with similar discriminatory capacity demonstrated in an external cohort (under peer review).
EUSTAR Activity Index
Currently, the only SSc disease activity index is the EUSTAR Activity Index (EScSG-AI), which was updated in 2017. 8, 9, 33 The EScSG-AI was developed from the multi-centre EUSTAR cohort, and items were generated by identifying disease manifestations that correlated with experts' assessment of disease activity.
The revised 2017 EScSG-AI is a 10-point weighted score of patient-reported worsening skin involvement over the preceding month, digital ulcers, elevated mRSS, tendon friction rubs, elevated C-reactive protein (CRP) and diffusing capacity for carbon monoxide (DLCO) less than 70% predicted. When published in 2001, the EScSG-AI included elevated erythrocyte sedimentation rate (ESR) in lieu of CRP; sclerodema; digital necrosis; patient-reported change in vascular, articular and cardiopulmonary symptoms in the preceding month; arthritis and hypocomplementaemia. 8 The EScSG-AI has faced criticism of its face and content validity as it does not capture gastrointestinal or renal disease activity, 9 and in the revised index, there are only limited measures of cardiopulmonary involvement. The revised index may also lack face validity as mRSS and DLCO at a given time-point may not be considered by SSc experts to represent disease activity.
Assessment of the 2001 EScSG-AI in an external cohort has shown moderate correlation of the score with physician global assessment of disease activity. 34 Skin involvement and sclerodema have a preponderant effect on the EScSG-AI, and activity initially captured in other organ systems persists over time, suggesting limited responsiveness to change. 35 The revised EScSG-AI has been partially validated in a cohort from within the EUSTAR study. A score of ≥3 identified active disease, as judged by experts, with a sensitivity of 52.2% and specificity of 89.1%. 9 The criterion validity of the revised EScSG-AI is yet to be tested against outcomes of morbidity, damage and mortality. Importantly, an activity index could spuriously demonstrate criterion validity by showing a strong relationship to an outcome such as morbidity or mortality, but this does not ensure that the items within the index have face and content validity for activity per se.
Measuring activity in SSc
Capturing disease activity in SSc presents significant challenges. 7, 36, 37 SSc is a multi-system disease with significant accrual of organ involvement early in the disease course, and damage can accrue throughout periods of apparent clinical quiescence. 18 Furthermore, the definition of the concept of disease activity in SSc is inconsistent in the literature.
Activity pertains to those aspects of disease that are reversible with time or therapy. 36, 37 Manifestations of SSc such as synovitis or myositis fulfil these criteria as inflammatory arthritis characteristically relapses and remits over time and inflammatory muscle disease responds to corticosteroid therapy.
In contrast, damage is the irreversible consequence of unchecked disease activity. 36 The accrual of organ damage results in end-organ dysfunction and mortality. When defining activity in SSc, it can be useful to consider activity on a continuum to damage and ultimately death. For example, pulmonary arterial hypertension (PAH) is one of the leading causes of SSc-related death. 17, 38 PAH is the clinical manifestation of pulmonary vasculopathy caused by endothelial dysfunction. The early identification of PAH in its 'active' phase remains challenging as systemic markers of vasculopathic manifestations of SSc are lacking. 39 Defining activity is complicated by the lack of definitions of organ involvement for particular SSc-affected systems, for example, cardiac disease. There is no expert agreement as to the definition of primary cardiac involvement; therefore, measures of the pathological processes causing ultimate cardiac dysfunction remain elusive. 17, 40 Due to the rapid progression and early mortality seen in dcSSc, 38 much research effort has been invested in outcome measures and therapeutic strategies to target this group of patients. Many outcome measures are able to assess patients with dcSSc but not lcSSc, neglecting the damage accrual that occurs in patients with lcSSc. 41 Owing to its rarity, there are few organ-specific outcome measures developed or validated for SSc. The 6-minute walk test (6MWT) was developed to measure exercise capacity in patients with cardiac failure and respiratory disease. 42 It is a commonly used end point in SSc-lungrelated trials but has not been fully validated for use in SSc 24 and is unable to account for the multi-system nature of SSc. Results of a 6MWT correlate with many different organ manifestations and are confounded by many disease-specific factors including chest wall and other musculoskeletal involvement. 43 
The OMERACT filter
In an effort to improve the quality of outcome measures used in clinical trials, the OMERACT network was established in 1992. 44 The OMERACT filter (Table 1) provides a standard to which any outcome measure should be compared before use in a clinical trial. The explicit framework assists in the selection of outcome measures and provides a structure for the development of new instruments. 12 Table 1 . OMERACT filter checklist of psychometric properties of the proposed SCTC Activity Index.
Truth -does the instrument measure what is intended?
Face The OMERACT filter has three component criteria: truth, discrimination and feasibility. 44 Truth refers to the face, content, construct and criterion validity of an outcome measure; namely, does the instrument have 'face value' and measure what is intended, can it capture the range of possibilities associated with the disease state and how does the new instrument compare to a gold standard? The reliability and sensitivity to change of an instrument determines its discriminatory capacity, and feasibility refers to the time, cost and ease of use of an outcome measure. 12, 44 
SCTC Activity Index
To address the lack of a fully validated SSc-specific activity index, the SCTC has convened a Working Group to develop an activity index (SCTC-AI), using the framework of the OMERACT filter and consensus and datadriven methods.
Development of the SCTC-AI: conceptual definition of disease activity
The Working Group will participate in a survey and faceto-face discussions regarding the conceptual definition of disease activity in SSc. A clear definition of disease activity is paramount to ensure a unanimous end goal when considering which items to include in the final index.
Development of the SCTC-AI: item generation, reduction and weighting
Provisional activity index items will be generated from literature review and expert opinion, including non-rheumatologist advisors and patient partners. Members of the SCTC will be invited to participate in a survey to rate the appropriateness of the proposed items.
Remaining items will be weighted against the following end points, using data from the Australian Scleroderma Cohort Study (ASCS):
1. Morbidity, defined by the physical component score of the Short Form-36 (SF-36) questionnaire; 2. Damage, defined by the SCTC-DI; 3. Mortality using time-dependent hazards regression models.
The discriminatory capacity of the SCTC-AI in the derivation cohort will be analysed using receiver operating characteristic curves.
Validation of SCTC-AI
External validation of the SCTC-AI will be performed in the Canadian Scleroderma Research Group (CSRG) Cohort Study, testing the association of disease activity with morbidity, damage and mortality. The ASCS and CSRG Cohort Study are both prospective, multi-centre, cohort studies of patients with generally long-standing disease. This will enable evaluation of the activity index in predicting damage accrual as well as responsiveness to change over time.
Given the early accrual of damage and mortality in SSc and the 'survivor bias' of cohorts with long-standing disease at recruitment, 38 the SCTC-AI will be prospectively validated in the International Systemic Sclerosis Inception Cohort (INSYNC) Study. Testing the index in both incident and prevalent cohorts will ensure the reliability and feasibility of the SCTC-AI across the spectrum of SSc disease.
Further testing of the SCTC-AI in post hoc analysis of existing trial data sets will evaluate its responsiveness over time and discriminant capability, leading to use of the SCTC-AI as an exploratory end point in future clinical trials.
Our proposed methodology aims to overcome the criticisms faced by previous indices, in particular difficulties with face, content and criterion validity reported in the EScSG-AI 45 (see Table 1 ). Careful attention will be paid to the construct validity of the items included in the final SCTC-AI, to ensure that the final index measures activity as intended in the activity definition developed by the SCTC Working Group. Accurately identifying patients in a high-disease activity state potentially offers a therapeutic window in which manifestations of disease may be reversible. Such patients may not be accurately identified by currently available outcome measures because the tool focuses on a single organ system, may be disproportionately affected by particular organ systems or are not SScspecific. Having a single, multi-system outcome measure that reflects overall disease activity may present a novel opportunity to accurately quantify the level of disease activity and target potentially efficacious therapies to those patients most likely to benefit from treatment.
Conclusion
There remains no consensus as to the concept of disease activity in SSc and no fully validated instrument to measure activity. By carefully adhering to the OMERACT filter, the SCTC-AI aims to address both of these issues and overcome the weaknesses of previously published SSc outcome measures.
An activity index that can reliably discriminate between high and low SSc disease activity states offers the opportunity to define and measure an elusive concept in SSc. The SCTC-AI should provide a clear and quantifiable end point for clinical trials and aid the development of diseasemodifying therapies. 
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